PET/CT scans to track early response to immunotherapy in head and neck cancer
Studies adults with recurrent or spreading head and neck cancer on pembrolizumab.
Plain-language title generated from the registry record
Registry title: Impact of Early Response to First-line Anti-PD-1 Monotherapy in Patients With Recurrent and/or Metastatic (R/M) Head and Neck Squamous Cell Carcinoma, Assessed by 18F-FDG PET/CT
Key facts
- Where
- Rome, ItalySee the site
Where in Italy
- Tor Vergata University HospitalRome, ItalyTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- University of Rome Tor Vergata
- Trial code
- NCT07448727
- Record updated
- 4 March 2026
- Original description
This study aims to evaluate the role of early response assessment by 18F-FDG PET/CT in patients with recurrent and/or metastatic (R/M) head and neck squamous cell carcinoma with PD-L1 CPS >1 treated with pembrolizumab monotherapy, in accordance with routine clinical practice.Read full original descriptionShow less
Prospective Observational Study On The Impact Of Early Response To First-line Anti-PD-1 Therapy In Patients With Recurrent And/Or Metastatic (R/M) Head And Neck Squamous Cell Carcinoma, Assessed By 18F-FDG PET/CT
This study aims to evaluate the role of early response assessment by 18F-FDG PET/CT in patients with recurrent and/or metastatic (R/M) head and neck squamous cell carcinoma with PD-L1 CPS >1 treated with pembrolizumab monotherapy, in accordance with routine clinical practice.
Inclusion: Histological diagnosis of recurrent and/or metastatic HNSCC, not amenable for curative locoregional treatment (either surgery or radiotherapy), and amenable for first line systemic treatment; CPS PD-L1 >=1.
Exclusion: Any controindication to immune checkpoint inhibitors.